PrognomiQ introduced early outcomes for its ProVue Lung blood-based laboratory-developed check, displaying excessive sensitivity for detecting lung most cancers in high-risk people, based on an organization launch. The check detected early-stage illness with 83% sensitivity in an ongoing real-world examine.
In a cohort of 78 high-risk adults, the check precisely recognized eight lung cancers, 5 of which have been provisionally categorized as Stage I. All instances have been confirmed by tissue biopsy. The outcomes confirmed an total sensitivity of 89% throughout all phases at 54% specificity.
Individuals within the examine have been adults aged 50 and older with a smoking historical past of a minimum of 20 pack-years, in line with present US Preventive Companies Job Power screening tips. The findings have been generated by an Early Expertise Program launched in November 2025 with Penn Highlands Healthcare and Allegheny Well being Community.
“Excessive-performance detection of stage I lung cancers gives essentially the most medical utility, and it’s promising to see a blood-based check figuring out cancers at this earliest stage in our sufferers,” says Sandeep Bansal, medical director of the Lung Middle and Interventional Pulmonology at Penn Highlands Healthcare, in a launch.
The check is designed to enhance low-dose CT (LDCT) scanning, which presently faces limitations to adoption. In accordance with the corporate, fewer than 16% of the 14 million folks eligible for LDCT screening within the US truly bear the process.
“These thrilling preliminary findings help the concept that a blood-based check like ProVue Lung might assist broaden entry and convey extra sufferers into screening pathways for early detection, notably for early-stage illness,” says Ali Zaidi, medical director of lung and esophageal analysis at Allegheny Well being Community, in a launch.
The ProVue Lung check makes use of a proteomic signature to establish most cancers. Philip Ma, CEO of PrognomiQ, notes that the power to establish cancers amenable to healing therapies reinforces the potential for proteomics in medical settings.
“These outcomes present breakthrough and unprecedented efficiency, and the constant efficiency of our assay throughout cohorts of accelerating statistical rigor helps validate our technical differentiation and sturdy method to product design,” says Ma in a launch.
The Early Expertise Program is ongoing, with plans to broaden to further well being techniques within the coming months. PrognomiQ intends to current additional medical information at future scientific conferences and in peer-reviewed publications.
ID 119090223 © Angellodeco | Dreamstime.com
